By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Neurim Pharmaceuticals 

8 Hanechoshet Street

Tel-Aviv    69710  Israel
Phone: 972-3-7684911 Fax: 972-3-6494568


Drug Discovery

Company News
Neurim Pharmaceuticals Grants Exeltis Marketing Rights for Paediatric Prolonged-Release Melatonin ("PedPRM") In Spain 3/29/2017 11:20:43 AM
Neurim Pharmaceuticals Paediatric Prolonged-Release Melatonin ('PedPRM') To Be Marketed By Biocodex In France 3/13/2017 8:57:11 AM
Neurim Pharmaceuticals Release: Phase II Clinical Trial For Treatment Of Mild Alzheimer's Disease 3/7/2017 6:21:05 AM
Neurim Pharmaceuticals Paediatric Prolonged-Release Melatonin ("PedPRM") To Be Marketed By Kuhnil Pharmaceutical Company In South Korea 12/6/2016 12:15:29 PM
Neurim Pharmaceuticals Grants Aspen Pharmacare Australia Marketing Rights For Paediatric Prolonged-Release Melatonin ("PedPRM") In Australia And New Zealand 11/16/2016 11:23:19 AM
Neurim Pharmaceuticals Announces Positive Top-Line Results From Pivotal Phase III Trial Of Paediatric Prolonged-Release Melatonin (“Pedprm”) For Sleep Disturbances In Children With Autism Spectrum Disorders (ASD) 11/2/2016 7:20:58 AM
Neurim Pharmaceuticals Announces First Patients' Enrollments In ReCOGNITION - Phase II Clinical Trial Of Piromelatine For Mild Alzheimer's Disease 9/28/2016 11:04:10 AM
Neurim Pharmaceuticals Announces Publication Of Positive Effects Of Add-On Circadin® In Alzheimer's Disease Patients 6/19/2014 7:15:03 AM
Neurim Pharmaceuticals: Circadin(R) - Prolonged Release Melatonin for Primary Insomnia is Licensed to Sigma Pharmaceuticals for Australia Markets 12/14/2009 10:36:04 AM
Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin(R) for Insomnia in Elderly Patients 6/11/2009 10:53:00 AM